| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MT1G |
| Uniprot No | P13640 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-59aa |
| 氨基酸序列 | MDPNCSCAAGVSCTCASSCKCKECKCTSCKKSCCSCCPVGCAKCAQGCICKGASEKCSC |
| 预测分子量 | 32.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于MT1G重组蛋白相关研究的模拟参考文献示例(文献信息为假设性描述，仅供格式参考)：
1. **标题**：*Recombinant Human MT1G Protein Attenuates Oxidative Stress in Hepatocellular Carcinoma Cells*
**作者**：Li X, Zhang Y, Chen Q.
**摘要**：本研究通过大肠杆菌表达系统成功纯化MT1G重组蛋白，并发现其通过螯合细胞内游离锌离子和清除ROS，显著抑制肝癌细胞的氧化应激损伤，提示其在癌症治疗中的潜在应用。
2. **标题**：*Expression Optimization and Metal-Binding Properties of Recombinant MT1G in Yeast*
**作者**：Kim S, Park JH.
**摘要**：作者优化了毕赤酵母中MT1G的重组表达工艺，证明该蛋白对镉和铜具有高亲和力，为重金属解毒剂的开发提供了实验依据。
3. **标题**：*Structural Characterization of MT1G Recombinant Protein and Its Role in Cisplatin Resistance*
**作者**：García-Rojas P, et al.
**摘要**：通过核磁共振解析MT1G重组蛋白结构，发现其与顺铂结合后可减少药物对肾细胞的毒性，揭示了其在化疗耐药性中的分子机制。
4. **标题**：*MT1G Recombinant Protein Suppresses Inflammatory Responses in Macrophages via NF-κB Pathway*
**作者**：Wang R, et al.
**摘要**：研究表明，MT1G重组蛋白通过抑制NF-κB信号通路，降低巨噬细胞中炎症因子水平，为炎症性疾病治疗提供了新思路。
**备注**：以上文献为模拟内容，实际研究需通过PubMed、Web of Science等平台检索关键词“MT1G recombinant protein”获取真实数据。
**Background of MT1G Recombinant Protein**
MT1G (Metallothionein-1G) is a member of the metallothionein (MT) family, a group of cysteine-rich, low-molecular-weight proteins (6–7 kDa) that bind heavy metals via thiol groups. Primarily involved in metal ion homeostasis and detoxification, MTs play critical roles in protecting cells against oxidative stress, heavy metal toxicity, and DNA damage. MT1G, a human isoform encoded by the *MT1G* gene, is located on chromosome 16q13 and is regulated by metal ions (e.g., zinc, cadmium) and oxidative stress signals.
Structurally, MT1G contains 20 conserved cysteine residues (out of 61 amino acids) that form metal-thiolate clusters, enabling high-affinity binding to divalent heavy metals like zinc, copper, and cadmium. This binding capacity underpins its role in sequestering excess metals, mitigating toxicity, and modulating cellular redox balance. MT1G is also implicated in apoptosis regulation, immune response modulation, and chemoresistance in cancers, with studies linking its dysregulation to tumor progression and drug resistance.
Recombinant MT1G is produced using biotechnological platforms, often through *E. coli* or yeast expression systems. The protein is purified via affinity chromatography, leveraging tags like His-tags for isolation. Its recombinant form retains native metal-binding properties, making it valuable for *in vitro* studies on metal metabolism, oxidative stress mechanisms, and disease pathways. Additionally, it serves as a tool for environmental monitoring (e.g., biosensors for heavy metal detection) and potential therapeutic development, such as chelation therapy or adjunct treatments for metal-related disorders.
Research on recombinant MT1G continues to explore its dual role in cytoprotection and disease pathogenesis, offering insights into novel biomarkers or targets for cancer, neurodegenerative diseases, and environmental toxicity.
×
